Janney Capital Says Its Time To Buy uniQure N.V (NASDAQ:QURE). Will Stock Hit Their Target of $40.00?


Why Has Janney Capital Given uniQure N.V (NASDAQ:QURE) a $40.00 Price Target

Analysts at Janney Capital began issuing coverage on shares of uniQure N.V (NASDAQ:QURE) in an analyst note distributed on Tuesday morning. The firm set Buy rating on the $501.82M market cap company.

From a total of 8 analysts covering uniQure N.V. (NASDAQ:QURE) stock, 9 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $59.92 while the lowest target price is $36.95. The mean of all analyst targets is $44.18 with a 127.63% above today’s ($19.58) stock price. uniQure N.V. was the topic of 14 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. WallachBeth Capital maintained shares on December 1 with “Buy” rating. Oppenheimer maintained shares with “Outperform” rating and $50 target share price in a report from a September 21. TH Capital reinitiated QURE stock in a recent report from November 30 with “Buy” rating. Piper Jaffray maintained the rating on August 28. Piper Jaffray has a “Overweight” rating and a $40 price target on shares. Finally, Leerink Swann maintained the stock with “Outperform” rating in a report issued on a September 22.

Approximately 296,728 shares of stock traded hands. Uniqure NV (NASDAQ:QURE) has declined 26.58% since April 28, 2015 and is downtrending. It has underperformed by 24.96% the S&P500.

Janney Capital Says Its Time To Buy uniQure N.V (NASDAQ:QURE). Will Stock Hit Their Target of $40.00?

Analysts await Uniqure NV (NASDAQ:QURE) to reports earnings on December, 7. They expect $-0.58 earnings per share, up 7.94% or $0.05 from last year’s $-0.63 per share. After $-0.96 actual earnings per share reported by Uniqure NV for the previous quarter, Wall Street now forecasts -39.58% EPS growth.

Uniqure NV is a pharmaceutical company based in the Netherlands. The company has a market cap of $501.82 million. It is primarily engaged in the field of gene therapy for orphan diseases. It currently has negative earnings. The Firm is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

According to Zacks Investment Research, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.” Get a free copy of the Zacks research report on Uniqure NV (QURE)